[The clinical efficacy of the new delayed-action calcium antagonist Cordipin-Retard].
Cordipin-retard is one of the new highly effective slow-releasing hypotensive drugs from the calcium antagonists family. Single intake of the drug is equal to that of corinfar while prolonged treatment with cordipin-retard surpasses corinfar in hypotensive influence and duration of effect. No adverse effect of the drug on conductive system of the heart and myocardial contractility were established. Taking into consideration the fact that cordipin-retard markedly decreases total peripheral resistance without reducing hypersympathicotonia the drug may be recommended for monotherapy and first-step treatment of patients suffering from Ist and IInd stage hypertonic disease associated with eu- and hypokinetic haemodynamics.